Stevin Zorn is Executive Vice President and US site head for Neuroscience Research at Lundbeck Research USA since 2008. He is a member of Lundbeck's Global Research Leadership Team, Development Committee, R&D Management group, R&D Executive Committee and the US Management Group. His research focus is on discovering meaningful treatments to relieve suffering from both Psychiatric and Neurological diseases and is presently heading up Lundbeck's Disease Biology Unit on Neuroinflammation to discover breakthrough therapies for psycho-neurological diseases. Dr. Zorn received a BS degree in Chemistry from Lafayette College, Easton, PA, and MS and Ph.D. degrees in Neurotoxicology and Neuropharmacology, respectively, from the University of Texas Graduate School of Biomedical Sciences, Houston, TX. Subsequent postdoctoral research studies centered on basic research of brain and intracellular neuronal signaling mechanisms at the Rockefeller University, New York, NY, in Paul Greengard's, (Nobel Laureate) laboratory of Molecular and Cellular Neuroscience.
Prior to his current position, Dr. Zorn was with Pfizer Global Research and Development for nearly 20 years. He held positions including head of General Pharmacology, Alzheimer's Disease Development Team Leader, Head of Psychotherapeutics Biology, Head of Neuroscience Therapeutics, Co-Chaired the global Neuroscience Therapeutic Area Leadership Team including accountability for R&D as well as commercialization, and was Vice President and Global Therapeutic Area Head for Central Nervous System Disorders Research at Pfizer.
Dr. Zorn has extensive drug discovery and drug development experience across a broad range of neuro and psychiatric disorders and across the whole value chain for drug discovery and development. He has co-authored over 100 scientific research communications and patents and has contributed to the advancement of a wide variety of drug candidates. Several of these candidates, including the antipsychotic drug Geodon, which Dr. Zorn played a seminal role in discovering and developing, are now in clinical use helping to improve the lives of millions of patients suffering from CNS-related illnesses around the world.